WORKING TOWARD A MALARIA-FREE WORLD

Malaria prevention and detection will be critical to eliminating the disease. Abbott's test to detect malaria and financial support to Malaria No More prove our commitment to the cause.

malaria prevention

Apr 24 2019

In many parts of the world, a mosquito bite is a mostly harmless part of a hot summer day. In others, it can mean the difference between good health and illness, between life and death.

Malaria killed 435,000 people worldwide in 2017, according to the World Health Organization. The WHO considers the disease a public health crisis, and has set a target to reduce global malaria incidence and mortality rates by at least 90% by 2030. Malaria prevention and detection will be critical to reaching that goal.

That's where Abbott is helping.

Elimination is Within Our Reach

A malaria-free world is an ambitious goal, but an achievable one. The disease is preventable and treatable, and data from the WHO shows that it can be eliminated with the right level of investment and commitment. But effectively combatting the disease hinges on preventing and detecting it, especially in rural areas that are difficult to reach.

Consider India. In 2015, Prime Minister Narendra Modi set a goal of eliminating malaria in India by 2030. Two years later, India — a country of some 1.3 billion people that has the fourth-highest malaria burden in the world — launched its five-year National Strategic Plan for Malaria Elimination.

Between 2016 and 2017, the country saw a 24% decrease in malaria cases. Much of this progress was driven by Odisha, a remote state in northeast India that in 2016 carried 40% of the country's malaria burden.

Elimination efforts, spurred by expanded distribution of mosquito bed nets, rapid diagnostic testing and treatment, helped reduce  the number of malaria cases by more than 80% in Odisha between 2017 and 2018. There's a long way to go still, but the progress made in Odisha serves as a model for the global fight.

Every Minute Matters

Abbott is in a unique position to help that fight. That's why we're collaborating with the global advocacy non-profit group Malaria No More and the government of Odisha to provide medical supplies, technical expertise and funding to help eliminate the disease.

As part of that commitment, Abbott is supplying 1 million SD BIOLINE Malaria Ag P.f/P.v rapid diagnostic tests to strengthen Odisha's efforts to detect the disease. Abbott is also assisting with technical training to help Odisha's 47,000 community health workers, known as ASHAs (Accredited Social Health Activists), correctly administer the tests and interpret the results, ensuring a sustainable system for diagnosis and treatment.

The SD BIOLINE test to detect malaria delivers results in 15 minutes, which enables health workers to accurately diagnose the disease. The tests also provide valuable data that can inform health officials' understanding of the disease's patterns and trends. Think of it as a surveillance system: With the data in hand, officials in Odisha can target disease control strategies to where they'll have the most impact.

Building a Road Map for a Malaria-Free India

In addition to the tests and training, Abbott has also earmarked $750,000 over three years to support Malaria No More's work with Odisha's National Vector Borne Disease Control Program. The hope is that Odisha's malaria-elimination strategy can serve as a road map as other Indian states develop elimination efforts.

These projects are helping make one bold dream a reality: A malaria-free India — indeed, a malaria-free world — can't happen without the support and advocacy of global organizations such as Malaria No More, which advance actionable, successful and sustainable strategies to end malaria for good. We believe in their purpose and their fight, and we're committed to joining them and other organizations in every way we can.

true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?